Clinical Trial Update: Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy for gastric/gastroesophageal junction adenocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Gastroesophageal Junction Adenocarcinoma

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING